All In Biotech

Drug Trial Radar · NCT06653296

A Dose-Response Safety Study of ENX-102 in Patients With GAD

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ENX-102 and Determine a Dose-response for ENX-102 in Patients With Generalized Anxiety Disorder (GAD)

Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Dec 9, 2024

Primary completion

Jun 23, 2025

Study completion Jun 23, 2025

Sponsor

Lead sponsor
Engrail Therapeutics INCIndustry
Sponsor type
Industry
First posted
Oct 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD

Conditions

  • General Anxiety Disorder

Interventions

  • ENX-102Drug

    Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period

  • PlaceboDrug

    Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: 4 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • MAC Clinical Research

    Blackpool, United Kingdom

  • MAC Clinical Research

    Manchester, United Kingdom

  • MAC Clinical Research

    Liverpool, UK, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.